吲哚胺2，3-双加氧酶与肿瘤免疫耐受

doi:10.16689/j.cnki.cn11－9349/r.2019.04.022

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (810 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要人体免疫系统可以对肿瘤表达的多种异常抗原产生免疫反应，但肿瘤通过复杂的进化过程所致的免疫耐受现象能够降低宿主针对肿瘤的自身免疫反应，使宿主无法通过免疫系统对肿瘤细胞作出免疫应答。因此该现象可导致肿瘤细胞逃避宿主的免疫监视以及免疫系统的攻击，从而使肿瘤细胞得以在人体内增殖和转移。IDO是细胞内催化L-色氨酸经犬尿氨酸途径进行分解代谢的关键酶，也是一种与免疫抑制相关的酶。IDO在多种病理生理过程中促进机体免疫耐受的发生，因此与肿瘤的发生发展有密切关系。大量研究发现，IDO作为一种重要的抑制性免疫检查点，在肿瘤患者中其酶活性的增加会促进肿瘤免疫耐受现象的建立。随着IDO介导肿瘤免疫耐受相关分子机制的发现与证实，IDO抑制剂也已成为肿瘤免疫疗法中的关键研究领域。本文重点阐明IDO发现的起源过程、在正常人体和肿瘤患者中的表达情况、调节色氨酸代谢等免疫调节功能以及IDO诱导TME中肿瘤免疫耐受建立的几种重要机制，包括色氨酸耗竭、激活芳香烃受体、诱导调节性T细胞扩增与活化以及募集和激活大量骨髓来源的抑制性细胞等机制，以便能够为今后的深入研究和IDO抑制剂的治疗应用提供更广阔的思维。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章

关键词 ：吲哚胺2, 3-双加氧酶, 肿瘤, 免疫耐受

Abstract：The immune system of human has been described to be able to produce the immune response to multiple abnormal antigens by tumors. Nevertheless, the immune tolerance of tumors, which induced by complex evolutionary steps of tumors, can reduce the hosts autoimmune response to tumors. Therefore, the phenomenon of immune tolerance may cause tumor to evade the hosts immune surveillance and attacks from the hosts immune effector cells. In turn, tumors have the opportunity to proliferate and metabolize in the body. Indoleamine 2,3-dioxygenase （IDO） is a key enzyme entailed in immunosuppression that promotes the development of immune tolerance in a variety of pathophysiological processes. A large number of studies have found that IDO is an important inhibitory immune checkpoint, and the increase of its activity in patients will promote the establishment of immune tolerance. This article reviews the origin, expression and function of IDO as well as the mechanisms by which IDO promotes the establishment of tumor immune tolerance. Hence, the present review provides a broader perspective for IDOs further research and application in cancer therapy.

Key words： Indoleamine 2,3-dioxygenase Tumor Immune tolerance

基金资助:国家重点研发计划项目（2017YFC1309200）

通讯作者: 石汉平，电子邮箱：shihp@ccmu.edu.cn

引用本文:

张康平，张琪，于恺英，陈永兵，饶本强，石汉平. 吲哚胺2，3-双加氧酶与肿瘤免疫耐受[J]. 肿瘤代谢与营养电子杂志, 2019, 6(4): 505-510.
ZHANG Kang-ping, ZHANG Qi, YU Kai-ying, RAO Ben-qiang, SHI Han-ping. Indoleamine 2,3-dioxygenase and tumor immune tolerance. Electron J Metab Nutr Cancer, 2019, 6(4): 505-510.

1.Higuchi K, Hayaishi O. Enzymic formation of D-kynurenine from D-tryptophan. Arch Biochem Biophys. 1967；120（2）:397-403.
2.Najfeld V, Menninger J, Muhleman D, et al. Localization of indoleamine 2,3-dioxygenase gene （INDO） to chromosome 8p12-->p11 by fluorescent in situ hybridization. Cytogenet Cell Genet. 1993；64（3-4）:231-232.
3.Ball HJ, Sanchez-Perez A, Weiser S, et al. Characterization of an indoleamine 2,3-dioxygenase-like protein found in humans and mice. Gene. 2007；396（1）:203-213.
4.Metz R, Duhadaway JB, Kamasani U, et al. Novel tryptophan catabolic enzyme IDO2 is the preferred biochemical target of the antitumor indoleamine 2,3-dioxygenase inhibitory compound D-1-methyl-tryptophan. Cancer Res. 2007；67（15）:7082-7087.
5.van Baren N, Van den Eynde BJ. Tumoral immune resistance mediated by enzymes that degrade tryptophan. Cancer Immunol Res. 2015；3（9）:978-985.
6.Theate I, van Baren N, Pilotte L, et al. Extensive profiling of the expression of the indoleamine 2,3-dioxygenase 1 protein in normal and tumoral human tissues. Cancer Immunol Res. 2015；3（2）:161-172.
7.van Baren N, Van den Eynde BJ. Tryptophan-degrading enzymes in tumoral immune resistance. Front Immunol. 2015；6:34.
8.Watcharanurak K, Zang L, Nishikawa M, et al. Effects of upregulated indoleamine 2, 3-dioxygenase 1 by interferon gamma gene transfer on interferon gamma-mediated antitumor activity. Gene Ther. 2014；21（9）:794-801.
9.Prendergast GC, Metz R, Muller AJ, et al. IDO2 in immunomodulation and autoimmune disease. Front Immunol. 2014；5:585.
10.Badawy AA. Kynurenine pathway of tryptophan metabolism: regulatory and functional aspects. Int J Tryptophan Res. 2017；10:1178646917691938.
11.Munn DH. Blocking IDO activity to enhance anti-tumor immunity. Front Biosci （Elite Ed）. 2012；4:734-745.
12.Brandacher G, Perathoner A, Ladurner R, et al. Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer: effect on tumor-infiltrating T cells. Clin Cancer Res. 2006；12（4）:1144-1151.
13.Jung KH, LoRusso P, Burris H, et al. Phase I study of the indoleamine 2,3-dioxygenase 1 （IDO1） inhibitor Navoximod （GDC-0919） administered with PD-L1 inhibitor （Atezolizumab） in advanced solid tumors. Clin Cancer Res. 2019；25（11）:3220-3228.
14.de Jong RA, Nijman HW, Boezen HM, et al. Serum tryptophan and kynurenine concentrations as parameters for indoleamine 2,3-dioxygenase activity in patients with endometrial, ovarian, and vulvar cancer. Int J Gynecol Cancer. 2011；21（7）:1320-1327.
15.Kurdziel K, Ravizzini G, Croft B, et al. The evolving role of nuclear molecular imaging in cancer. Expert Opin Med Diagn. 2008；2（7）:829-842.
16.Sakurai K, Fujisaki S, Adachi K, et al. Indoleamine 2,3-dioxygenase activity during i131-radioisotope therapy for metastatic thyroid cancer］. Gan To Kagaku Ryoho. 2015；42（10）:1259-1261.
17.Zahm CD, Johnson LE, McNeel DG. Increased indoleamine 2,3-dioxygenase activity and expression in prostate cancer following targeted immunotherapy. Cancer Immunol Immunother. 2019；68（10）:1661-1669.
18.Chen JY, Li CF, Kuo CC, et al. Cancer/stroma interplay via cyclooxygenase-2 and indoleamine 2,3-dioxygenase promotes breast cancer progression. Breast Cancer Res. 2014；16（4）:410.
19.姜艳丽, 方艳秋, 芦小单, 等. 吲哚胺2,3-双加氧酶在良、恶性卵巢肿瘤中的表达及临床意义. 中国妇幼保健. 2014；（36）:6106-6108.
20.Mills A, Zadeh S, Sloan E, et al. Indoleamine 2,3-dioxygenase in endometrial cancer: a targetable mechanism of immune resistance in mismatch repair-deficient and intact endometrial carcinomas. Mod Pathol. 2018；31（8）:1282-1290.
21.Zhang T, Tan XL, Xu Y, et al. Expression and prognostic value of indoleamine 2,3-dioxygenase in pancreatic cancer. Chin Med J （Engl）. 2017；130（6）:710-716.
22.Wang Y, Yao R, Zhang L, et al. IDO and intra-tumoral neutrophils were independent prognostic factors for overall survival for hepatocellular carcinoma. J Clin Lab Anal. 2019:e22872.
23.Wainwright DA, Balyasnikova IV, Chang AL, et al. IDO expression in brain tumors increases the recruitment of regulatory T cells and negatively impacts survival. Clin Cancer Res. 2012；18（22）:6110-6121.
24.Munn DH, Zhou M, Attwood JT, et al. Prevention of allogeneic fetal rejection by tryptophan catabolism. Science. 1998；281（5380）:1191-1193.
25.Mellor AL, Chandler P, Lee GK, et al. Indoleamine 2,3-dioxygenase, immunosuppression and pregnancy. J Reprod Immunol. 2002；57（1-2）:143-150.
26.Wang Q, Liu D, Song P, Zou MH. Tryptophan-kynurenine pathway is dysregulated in inflammation, and immune activation. Front Biosci （Landmark Ed）. 2015；20:1116-1143.
27.Fujigaki H, Yamamoto Y, Saito K. L-Tryptophan-kynurenine pathway enzymes are therapeutic target for neuropsychiatric diseases: focus on cell type differences. Neuropharmacology. 2017；112（Pt B）:264-274.
28.Lima S, Kumar S, Gawandi V, et al. Crystal structure of the Homo sapiens kynureninase-3-hydroxyhippuric acid inhibitor complex: insights into the molecular basis of kynureninase substrate specificity. J Med Chem. 2009；52（2）:389-396.
29.倪晓琳, 胡润晖, 贺晨, 等. 犬尿氨酸途径代谢酶与肿瘤的研究进展. 重庆医科大学学报. 2017；（11）:1363-1365.
30.Munn DH. Indoleamine 2,3-dioxygenase, Tregs and cancer. Curr Med Chem. 2011；18（15）:2240-2246.
31.Suzuki S, Tone S, Takikawa O, et al. Expression of indoleamine 2,3-dioxygenase and tryptophan 2,3-dioxygenase in early concepti. Biochem J. 2001；355（Pt 2）:425-429.
32.Ciorba MA, Bettonville EE, McDonald KG, et al. Induction of IDO-1 by immunostimulatory DNA limits severity of experimental colitis. J Immunol. 2010；184（7）:3907-3916.
33.Moon YW, Hajjar J, Hwu P, et al. Targeting the indoleamine 2,3-dioxygenase pathway in cancer. J Immunother Cancer. 2015；3:51.
34.Johnson TS, Munn DH. Host indoleamine 2,3-dioxygenase: contribution to systemic acquired tumor tolerance. Immunol Invest. 2012；41（6-7）:765-797.
35.马齐襄, 朱晓丹, 胡凯文, 等. 肿瘤转移的种子与土壤学说新认识. 肿瘤防治研究. 2015；（10）:1049-1053.
36.Bauer TM, Jiga LP, Chuang JJ, et al. Studying the immunosuppressive role of indoleamine 2,3-dioxygenase: tryptophan metabolites suppress rat allogeneic T-cell responses in vitro and in vivo. Transpl Int. 2005；18（1）:95-100.
37.Metz R, Rust S, Duhadaway JB, et al. IDO inhibits a tryptophan sufficiency signal that stimulates mTOR: a novel IDO effector pathway targeted by D-1-methyl-tryptophan. Oncoimmunology. 2012；1（9）:1460-1468.
38.Harding HP, Novoa I, Zhang Y, et al. Regulated translation initiation controls stress-induced gene expression in mammalian cells. Mol Cell. 2000；6（5）:1099-1108.
39.Muller AJ, DuHadaway JB, Donover PS, et al. Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nat Med. 2005；11（3）:312-319.
40.王翠娟, 尚明, 邵华. 芳香烃受体在肿瘤发生及免疫治疗中的作用. 中华肿瘤防治杂志. 2018；（15）:1126-1130.
41.Opitz CA, Litzenburger UM, Sahm F, et al. An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor. Nature. 2011；478（7368）:197-203.
42.Hao K, Zhou Q, Chen W, et al. Possible role of the ‘IDO-AhR axis in maternal-foetal tolerance. Cell Biol Int. 2013；37（2）:105-108.
43.Boitano AE, Wang J, Romeo R, et al. Aryl hydrocarbon receptor antagonists promote the expansion of human hematopoietic stem cells. Science. 2010；329（5997）:1345-1348.
44.Balachandran VP, Cavnar MJ, Zeng S, et al. Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of IDO. Nat Med. 2011；17（9）:1094-1100.
45.Dons EM, Raimondi G, Cooper DK, et al. Induced regulatory T cells: mechanisms of conversion and suppressive potential. Hum Immunol. 2012；73（4）:328-334.
46.Hill M, Tanguy-Royer S, Royer P, et al. IDO expands human CD4+ CD25 high regulatory T cells by promoting maturation of LPS-treated dendritic cells. Eur J Immunol. 2007；37（11）:3054-3062.
47.Grohmann U, Orabona C, Fallarino F, et al. CTLA-4-Ig regulates tryptophan catabolism in vivo. Nat Immunol. 2002；3（11）:1097-1101.
48.Munn DH, Sharma MD, Mellor AL. Ligation of B7-1/B7-2 by human CD4+ T cells triggers indoleamine 2,3-dioxygenase activity in dendritic cells. J Immunol. 2004；172（7）:4100-4110.
49.Wood KJ, Sawitzki B. Interferon gamma: a crucial role in the function of induced regulatory T cells in vivo. Trends Immunol. 2006；27（4）:183-187.
50.Sharma MD, Baban B, Chandler P, et al. Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase. J Clin Invest. 2007；117（9）:2570-2582.
51.Pyzer AR, Cole L, Rosenblatt J, et al. Myeloid-derived suppressor cells as effectors of immune suppression in cancer. Int J Cancer 2016；139（9）:1915-1926.
52.Holmgaard RB, Zamarin D, Li Y, et al. Tumor-Expressed IDO recruits and activates MDSCs in a Treg-dependent manner. Cell Rep 2015；13（2）:412-424.
53.Su C, Zhang P, Liu J, et al. Erianin inhibits indoleamine 2,3-dioxygenase-induced tumor angiogenesis. Biomed Pharmacother. 2017；88:521-528.
54.Wei L, Zhu S, Li M, et al. High indoleamine 2,3-dioxygenase is correlated with microvessel density and worse prognosis in breast cancer. Front Immunol. 2018；9:724.
55.Marti LC, Pavon L, Severino P, et al. Vascular endothelial growth factor-A enhances indoleamine 2,3-dioxygenase expression by dendritic cells and subsequently impacts lymphocyte proliferation. Mem Inst Oswaldo Cruz. 2014；109（1）:70-79.